Drug
Aigiv KG
Aigiv KG: highest development phase Phase 1/2, developed by Emergent BioSolutions. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| AIGIV 3.5 mg/kg NCT00845650 | Phase 1/2 | Anthrax |
Latest
No recent events.
Follow Aigiv KG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.